These results indicate that loss of pyruvate dehydrogenase activity may be associated with either absent or catalytically inactive proteins, and in those cases in which this enzyme is absent, mRNA for one of the subunits may also be missing. When mRNA for one of the subunits is lacking, both protein subunits are absent, suggesting that a mutation affecting the expression of one of the subunit proteins causes the remaining uncomplexed subunit to be unstable. The results show that several different mutations account for the molecular heterogeneity of pyruvate dehydrogenase deficiency.
detectable crossreactive protein but had diminished amounts of mRNA for the a subunit of pyruvate dehydrogenase only.
These results indicate that loss of pyruvate dehydrogenase activity may be associated with either absent or catalytically inactive proteins, and in those cases in which this enzyme is absent, mRNA for one of the subunits may also be missing. When mRNA for one of the subunits is lacking, both protein subunits are absent, suggesting that a mutation affecting the expression of one of the subunit proteins causes the remaining uncomplexed subunit to be unstable. The results show that several different mutations account for the molecular heterogeneity of pyruvate dehydrogenase deficiency. 41 ,000 and 36,000 Da, respectively. E1 is a tetramer (a2 /32) and is present in multiple copies in the complex. Phosphorylation of Ela by E1 kinase inactivates E1, whereas dephosphorylation by phospho-El phosphatase restores catalytic activity (1, 2) .
PDHC deficient subjects have an enzymatic block that prevents entry of pyruvate into the tricarboxylic acid cycle. Individuals with this genetic disorder have both lactic acidosis and neurologic disability ranging from severe brain stem dysfunction incompatible with life to moderate ataxia with otherwise normal mental development (4) (5) (6) (7) (8) (9) . Defects involving either the catalytic or regulatory components of PDHC have been described (4, 5, 8) . Although in many reported cases identification of the affected component has not been well established, defects of E1 appear to be most common (4) .
Characterization of deficiency states has depended on determination of the activity of PDHC and its components (4, 10, 11) . Recently, antibodies raised against PDHC or its components have been employed in immunoassays to identify abnormalities at the protein level (12) (13) (14) (15) (16) . Several laboratories, including ours, have isolated cDNAs coding for the Ela, E1P, E2, and E3 components of human PDHC (17) (18) (19) (20) (21) (22) (23) . A human Ela cDNA was used to analyze mRNA from three patients with E1 deficiency (17) .
We investigated 11 patients with E1 deficiency using a comprehensive approach combining measurements of enzyme activity, protein immunoreactivity, and specific mRNAs. Our findings demonstrate significant heterogeneity in the expression of E1 deficiency.
SUBJECTS AND METHODS
Identification of El-Deficient Subjects. El-deficient patients were identified by assaying the activity of PDHC, PDHC components, and related enzymes in cultured skin fibroblasts. Fibroblasts were obtained from either patients with lactic acidosis of undetermined etiology or subjects in whom the diagnosis of (6, 12, 13, 24, 25) .
Measurement of Enzyme Activity. For assay of enzyme activity, skin fibroblasts were grown until confluent and harvested (13) . Lymphocytes were isolated from anticoagulated blood by the Ficoll-Paque method; whole tissue fragments were kept frozen at -70'C and then homogenized for assay as described (13) . PDHC (13) .
The E1 component of PDHC was assayed in a similar manner except that coenzyme A and NAD + were omitted from the assay, and ferricyanide was added (13) . Activity of E2, E3, pyruvate carboxylase, phosphoenolpyruvate carboxykinase, and citrate synthase were assayed by described methods (11, 13, 26, 27) . Normal ranges of activity for PDHC, its components, and other mitochondrial enzymes in cells or tissues have been established in our laboratory (13, 14) . Subjects selected for this study had abnormally low total PDHC and E1 activities but normal activities of E2, E3, and other mitochondrial enzymes.
Immunoblots. Immunoassays, using NaDodSO4/PAGE and electrotransfer (immunoblot), were done on fibroblast specimens as described elsewhere (12) . Immunoblots were incubated with specific antibodies for Ela and E1p (affinity purified as described below) (20) (31) with RNA from fibroblasts of non-PDHC-deficient subjects as controls. 32P-labeled probes were prepared from denatured double-stranded cDNAs using the random priming method (32, 33) . For E1a, the 1.4-kb cDNA clone was used as a template, whereas for E1p, a mixture of 1.0-and 0.5-kb EcoRI fragments from a digest of a 1.5-kb E1l3 clone were labeled (20) . A radiolabeled 1.1-kb fragment containing the 5' end of the 2.2-kb E3 cDNA was used as an internal control (22) . Membranes were rehybridized with successive cDNA probes after removing previously used radioactive probes (34) . The relative amount of specific mRNAs was determined for selected radiographs by laser densitometry (Ultroscan; LKB, Bromma, Sweden).
RESULTS Nine of 132 individuals with lactic acidosis that we screened fulfilled the criteria for having E1 deficiency. Two other El-deficient subjects were referred to us by other investigators. All 11 had PDHC activity below the normal range in cultured skin fibroblasts; 8 subjects for whom additional samples were available also had low levels of activity in lymphocytes or other tissues ( Table 1 ). All of the subjects' fibroblasts had levels of E1 activity that were low relative to both the normal range established in our laboratory and to concurrent controls ( Table 2) . Activities of E2 and E3 were normal. Ten subjects had normal activity for three other mitochondrial enzymes-pyruvate carboxylase, phosphoenolpyruvate carboxykinase, and citrate synthase (Table  1 )-indicating satisfactory cell culture conditions or postmortem tissue recovery. One subject, JH, had normal levels of phosphoenolpyruvate carboxykinase, citrate synthase, E2, and E3, with slightly reduced levels of pyruvate carboxylase. However, PDHC and E1 activity in this individual were well below the range of normal. In three subjects from whom tissues were available (GB, PH, and BK), preincubation with phospho-E1 phosphatase resulted in no increase of total PDHC activity; PDHC activity did increase in concurrent controls, indicating that lack of phosphatase was not the cause of low PDHC activity in these three cases.
Assay of PDHC components by immunoblotting was performed with fibroblasts from all 11 subjects to determine whether low E1 activity was associated with lack of protein or presence of abnormal protein. Two patterns emerged from this investigation. Seven patients had immune crossreactive material (CRM +) present for both Ela and E1,f ( Table 2 ). The other 4 subjects had no or barely detectable crossreactive material (CRM-) for either Ela or E13. All of the CRMpatients had normal levels of crossreactive material for E2 and E3, demonstrating adequate loading and transfer of proteins to the membrane (data not shown). Examples of patients who are either CRM+ or CRM-are shown in Fig.  1 . In our immunoblots, E1a appeared as a doublet. The separation of E1a into a doublet may under certain conditions be due to the state of phosphorylation (35) . Patient BK (Fig.  1, lane 7) who is CRM+ had an additional reactive protein band with a molecular mass corresponding to -43 kDa as estimated in relation to the mobility of other PDHC components. Other examples of CRM -immunoblots of either fibroblasts and/or tissue samples from patients JS and EU have been published (12, 13) . Subjects who were CRM + had (17, 19) , there are two different molecular-size species of E1a mRNA in normal subjects (Fig. 2, Top, lanes 2, 4, 6, 8 , and 10). The more intense band corresponds to a 1.6-kb species, and the less intense band corresponds to a 3.3-kb species. For CRM-subjects, two patterns were discernible (summarized in Table 2 ). Two ofthe four subjects (EU and PH) had normal levels ofboth Ela mRNA species (Fig. 2, Top, lanes 1 and 9) .
The other two CRM-subjects (JS and JH) had decreased amounts of E1a mRNA as compared to controls (Fig. 2 , Top, lanes 3 and 7, respectively). For JS, both the 1.6-kb and 3.3-kb species of Ela mRNA were present at low levels, whereas in JH, only the 1.6-kb E1a mRNA could be detected even after prolonged radiographic exposure. These differences were confirmed by densitometry and repeat RNA blots using different concentrations oftotal RNA (data not shown).
All four CRM-samples had normal levels of E1,8 mRNA with a size of 1.5 kb, similar to the controls (Fig. 2, Middle) . RNA membrane demonstrated normal levels of E3 mRNA in all the samples (Fig. 2, Bottom) , indicating that comparable amounts of RNA from each sample had been transferred to the membrane. The ages of the eleven E1-deficient subjects at the time of evaluation ranged from 2 days to 17 years; six subjects have died. The five survivors have significant morbidity ranging from abnormal brain development to ataxia with otherwise normal mental development (Table 1) . No correlation was found between clinical severity of disease and levels of activity of PDHC or E1. Similarly, no association could be found between clinical severity of PDHC deficiency and absence of immunoreactive E1 subunits or Ela mRNA. The two patients missing Ela mRNA differed dramatically in the severity of their symptoms. Patient JH is alive with moderate ataxia, whereas JS died after a more severe course and had pathological evidence of Leigh disease (24) .
DISCUSSION
In this series of eleven patients, E1 deficiency was comprehensively characterized at the activity, protein, and mRNA The association oflow enzymatic activity without evidence of an immunologically detectable abnormality of E1 has been noted by others (15, 16) . Several possible types of mutations might cause low E1 activity without resulting in any absence of immunoreactive protein. A change in the primary amino acid sequence of either subunit could alter the catalytic activity of this rate-limiting component. Alternatively, defective phospho-E1 phosphatase could account for the lack of E1 activity because E1 would remain in a fully phosphorylated (inactive) form. We were able to exclude this possibility in two CRM + patients (BK and GB) from whom tissues were available by demonstrating failure of activation upon adding exogenous phospho-E1 phosphatase. Finally, it is conceivable that the primary defect in these patients does not involve either E1 subunit and the low activity detected by enzymatic assay of E1 is incidental. Considering that the E1 assay measures <5% of total PDHC activity, errors could occur in this measurement because the differences between normal and abnormal values are relatively small (8) . We found that this assay is reliable for measurement of E1 in isolated mitochondria from liver or muscle (13, 14) , but the assay in disrupted skin fibroblasts must be interpreted very cautiously. In CRM + cases in which only fibroblasts are available for analysis, the diagnosis of E1 deficiency should be supported by evidence of normal E2 and E3 activity in addition to low E1 and total PDHC activity. This approach was followed for all patients in our series.
Our findings differ from those of McKay et al. (16) , who described altered electrophoretic mobility in three CRM + patients with E1 deficiency whose E1a protein migrated to a position corresponding to a molecular mass of 41 
